10.57
-0.64 (-5.71%)
| Previous Close | 11.21 |
| Open | 11.38 |
| Volume | 794,084 |
| Avg. Volume (3M) | 1,122,179 |
| Market Cap | 832,902,336 |
| Price / Sales | 5.90 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -3.5 |
| Average | 0.00 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2025 | 7,464,572 |
| 52 Weeks Range | ||
| Median | 25.00 (136.52%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 27 Feb 2026 | 25.00 (136.52%) | Buy | 12.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PARIKH ASIT | 11.11 | 11.11 | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | 11.11 | |||
| Aggregate Avg. Sell ($) | 11.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PARIKH ASIT | Director | 10 Mar 2026 | Disposed (-) | 40,000 | 11.11 | 444,400 |
| PARIKH ASIT | Director | 10 Mar 2026 | Acquired (+) | 40,000 | 11.11 | 444,400 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |